Frankfurt
02.06.26 | 08:14
0,053 Euro
+4,13 % +0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | Isofol Medical AB: Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026 | 366 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the "Company") held its annual general meeting (the "AGM") today. The following resolutions, in principle, were... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 19.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - March 2026 | 112 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - March 2026 is now... ► Artikel lesen | |
| 15.04. | Isofol Medical AB: Isofol optimizes the design of its phase Ib/II study following new regulatory approval | 378 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized design for the company's... ► Artikel lesen | |
| 18.03. | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | 1.171 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| 11.03. | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | 294 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| 24.02. | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 322 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 167 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen | |
| 13.11.25 | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | 296 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| 12.11.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2025 | 234 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January-September 2025... ► Artikel lesen | |
| 30.09.25 | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | 424 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen | |
| 26.09.25 | Isofol Medical AB: Isofol completes transfer of shares to Solasia Pharma following a successful rights issue | 303 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the shares subscribed by the Japanese collaboration partner Solasia... ► Artikel lesen | |
| 26.08.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | 242 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen | |
| 16.07.25 | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | 332 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
| 12.06.25 | Isofol Medical AB: Isofol completes first cohort in ongoing clinical study with arfolitixorin | 432 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, June 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the first cohort in the ongoing phase Ib/II clinical study with... ► Artikel lesen | |
| 12.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.06.2025 | 575 | Xetra Newsboard | Das Instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY wird ex Kapitalmassnahme gehandelt am 12.06.2025 The instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.06.25 | Isofol Medical AB: Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on 11 June 2025 | 302 | GlobeNewswire (Europe) | GOTHENBURG, 11 June 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at which the following main resolutions were passed by the shareholders.
The... ► Artikel lesen | |
| 05.06.25 | Isofol Medical AB: Isofol announces final terms of the rights issue and the potential overallotment issue | 362 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 5 June 2025 - The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol" or the "Company") announced on 12 May 2025, that the Board of Directors, subject... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,352 | -6,44 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.05.2026 / 17:08 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,800 | -0,17 % | Intellia to present Phase 3 gene editing trial data at congress | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,340 | -1,72 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,036 | -1,33 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| ATAIBECKLEY | 4,180 | +0,97 % | Wall Street entdeckt Psychedelika - steht Emyria vor einer Neubewertung? | ||
| BIOMERIEUX | 70,00 | -1,82 % | BIOMERIEUX: bioMérieux invests in France with a new facility to produce innovative diagnostics for the European market | ||
| BIO GREEN MED SOLUTION | 1,070 | -2,73 % | Bio Green Med Solution, Inc. - 8-K, Current Report | ||
| GENUS | 25,800 | -7,19 % | Dividendenbekanntmachungen (05.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN ASSETS TRUST INC US0240131047 0,34 USD 0,2922 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2914 EUR ASSOCIATED... ► Artikel lesen | |
| ANAPTYSBIO | 45,500 | -0,35 % | AnaptysBio, Inc.: Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update | Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations businessNow exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with VandaAnnounced... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,870 | -1,58 % | XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq | RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter")... ► Artikel lesen | |
| MEIRAGTX | 8,950 | +5,92 % | MeiraGTx Reports First Quarter 2026 Financial and Operational Results | Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered... ► Artikel lesen | |
| ABIONYX PHARMA | 2,740 | -3,18 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026 | Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded... ► Artikel lesen | |
| AKESO | 11,755 | -9,44 % | BofAS Raises AKESO TP to HKD164, Reiterates Buy Rating | ||
| MAAT PHARMA | 2,870 | +0,35 % | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 | MaaT013 (Xervyteg):
In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,002 (+4,13 %) liegt der Kurs bei 0,053 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.